Recent recommendations from the IKWG [19, 53] report that sufficient levels of evidence of the prognostic value of Ki-67 exists only in the setting of ER-positive early-stage breast cancer, where levels ≥ 5% and ≥ 30%, respectively, may favour withholding or administration of chemotherapy. Here, MKI67 is linked to breast cancer.